Ivonescimab

Ivonescimab is a humanized bispecific monoclonal antibody currently being trialed for use against non-small-cell lung cancer.

Uses your system voice; voice and rate in settings.

Snapshot

≈ 1 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Ivonescimab is a humanized bispecific monoclonal antibody currently being trialed for use against non-small-cell lung cancer. Developed by Akeso, it has been approved in China for the treatment of epidermal growth factor receptor-mutated locally advanced or metastatic non-squamous NSCLC in patients who have progressed past tyrosine kinase inhibitor therapy, and is undergoing clinical trials elsewhere.

Mechanism of action

Ivonescimab prevents tumor proliferation and angiogenesis by inhibiting programmed cell death protein 1 and vascular endothelial growth factor A, respectively.

Research

Ivonescimab so far has only completed trials in Chinese patients, and is currently undergoing phase III trials in the United States for the treatment of non-squamous non-small-cell lung cancer and advanced NSCLC.

Society and culture

The initial success of ivonescimab in trials is compared to already-approved drugs such as Merck & Co.'s Keytruda (pembrolizumab); its success has been described as important for the pharmaceutical industry in China.

See also

Nivolumab Pembrolizumab

Text derived from https://en.wikipedia.org/w/index.php?oldid=1335541545 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

4 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.